The NGS Based Diagnostics Market Is To Be Going The Subscription-Based Services Way

Next-generation sequencing (NGS) -based diagnostics are medical devices used to diagnose a variety of conditions using advanced-generation sequencing platforms. Unlike previous versions of the first-generation dideoxy “Sanger” sequence, they can simultaneously perform parallel sequences of multiple genomes within two weeks using a single instrument.

Their sensitivity, high speed, and reduced cost per sample make it a very profitable platform compared to other platforms. Their main use is in the early diagnosis of various types of cancer caused by genomic changes such as mutations.

Apart from that, they can be used to study the genomic sequences of rapidly transforming drug-resistant pathogens. Diagnostic virology is another most successful advance in NGS diagnosis that has discovered and characterized new viruses. Over the last decade, multiple sequencing platforms have been launched that offer a variety of sequencing approaches, including whole genome sequencing (WGS), whole exome sequencing (WES), and amplicon sequencing.

Get a sample copy of this report @ https://www.persistencemarketresearch.com/samples/15784

The global Next Generation Sequencing (NGS) based diagnostics market is segmented based on sequencing type, application, end user, and region.

Based on the type of sequencing, the global next-generation sequencing (NGS) -based diagnostic market is categorized as follows:

• DNA sequencing
• RNA sequencing
• Whole genome sequence
• Whole exome sequence
• Paired end sequence
• Single read sequence
• Multiplex sequence
• Deep sequence

Based on the application, the next-generation sequencing (NGS) -based diagnostic market is divided as follows:

• Cancer diagnosis
• Diagnosis of connective tissue disorders
• Diagnosis of inborn errors of metabolism
• Diagnosis of neurodegenerative diseases
• Diagnosis of Fanconi anemia
• Diagnosis of lysosomal storage disease

Based on the end user, the next generation sequencing (NGS) based diagnostics market is divided as follows:

• hospital
• clinic
• Scholar / Research Institute

Request a table of contents here for a complete list of market players @  https://www.persistencemarketresearch.com/toc/15784

The global next-generation sequencing (NGS) -based diagnostics market is showing exponential growth as several new players use the platform to enter this space. Established players are reforming technology to compete with other players. The market is very fragmented due to the large number of players. Universities and other research institutes are important contributors to this market.

Geographically, the next-generation sequencing (NGS) -based diagnostic market is divided into regions. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, Middle East, Africa. North America is currently leading the market with research, innovation and the presence of the largest number of players.

Europe follows the United States. The increasing number of cancer cases and the incidence of drug-resistant infections in Asian and African countries have created a great demand for such techniques. Therefore, the market grows at a fast pace in these regions.

Book Now for Exclusive Analyst Support @  https://www.persistencemarketresearch.com/checkout/15784

Janssen Global Services, LLC, F are the leading companies in the global next-generation sequencing (NGS) -based diagnostics market. Hoffmann La Roche Ltd., QIAGEN, Oxford Gene Technology, Illumina, Inc., ThermoFisher Scientific, Pacific Biosciences, Paradigm Diagnostics Inc. , Innogene Kalbiotech, Admera Health, AITbiotech Pte Ltd, CENTOGENE AG, Phalanx Biotech Group, iGenomX.

About Us :-